Human Amniotic Membrane
Phase 2Biologic
Human Amniotic Membrane is one of 43 biologic programs targeting Osteonecrosis. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Calan
VVal Adams
Preclinical
Human Amniotic Membrane
UUniversity of Utah
Phase 2
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteonecrosis1 trial
Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management
Recruiting·—·Phase 2·NCT05664815·66 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Human Amniotic Membrane. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Utah